Horizon Licenses Harvard Gene Editing IP | GenomeWeb

NEW YORK (GenomeWeb News) – Horizon Discovery announced today that it has licensed non-exclusive rights to Harvard University's intellectual property covering gene-editing technology.

The Cambridge, UK-based firm said the license covers the commercialization of products that utilize Harvard's CRISPR gene-editing technology for research use. CRISPR is an RNA-guided gene editing system that can introduce either a targeted double strand break or single strand nick in the genome of mammalian cells.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.